

VIVALIS SIGNS A NEW EVALUATION AGREEMENT FOR PROTEIN PRODUCTION IN THE EB66[®] CELL LINE

Nantes, Lyon (France), October 5, 2010 – VIVALIS (NYSE Euronext: VLS), a biopharmaceutical company, announced today that it has signed with an undisclosed partner an agreement to evaluate the EB66[®] cell line for the production of several, undisclosed therapeutic proteins.

Under this agreement, VIVALIS will develop several therapeutic protein candidates in the EB66[®] cell line with the partner assessing protein characteristics. The results of this feasibility study would result in an EB66[®] cell line commercial license to the partner.

Terms of the agreement were not disclosed.

"We are very pleased to add another partner to the list of groups evaluating the potential of Vivalis'EB66[®] cell line. This is the fifth EB66[®] cell line agreement signed since beginning of 2010. Through a year of active promotion in the highly fragmented therapeutic protein field, we have increased our EB66[®] awareness in a market having sales three times higher than those for vaccines. We are very satisfied that the progress we have made in the vaccine field with the EB66[®] cell line is now increasingly referenced in the therapeutic protein field," said Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS.

Next Financial Press Release

October 20, 2010: Third Quarter Revenues for 2010 (after NYSE Euronext market close)

About The EB66[®] Cell Line

The EB66[®] cell line, derived from avian embryonic stem cells, presents unique industrial and regulatory characteristics, such as long-term genetic stability, immortality and cell growth up to high cell densities in suspension using serum-free media (>40 million cells/mL).

EB66[®] cells replicate a wide range of human and animal viruses and are currently used for the production of investigational viral vaccines by many major vaccine developers.

A Biologics Master File (BMF) for the EB66[®] cell line with the U.S. Food and Drug Administration (FDA) was filed on June 27, 2008 and is updated annually.

EB66[®] cells are also easily engineered to express recombinant proteins of interest (> 1.0 g/l). Monoclonal antibodies produced in EB66[®] cells have a human-like glycosylation profile with the additional benefits of reduced fucose content. This latter characteristic provides increased cytotoxic activity (ADCC) to antibodies, which may be useful in the treatment of cancer and infectious disease.

About VIVALIS (www.vivalis.com)

VIVALIS (Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in three main areas:

EB66[®] Cell Line

VIVALIS offers research and commercial licenses for its EB66[®] cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). Through these programs VIVALIS receives upfront, clinical, and milestone payments along with royalties on licensees net sales.

Humalex[®] Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of fully human monoclonal antibodies is now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical, and milestone payments along with royalties on licensees net sales.

3D-Screen Platform

VIVALIS performs discovery and early stage development of small molecules identified with VIVALIS' proprietary 3D-Screen platform, which identifies target protein conformational modulators. VIVALIS is also building a portfolio of proprietary products for the treatment of hepatitis-C infection using this platform.

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,500 employees), a world-wide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL, Kaketsuken, Merial, Intervet, SAFC Biosciences. VIVALIS is a member of both the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bio-clusters.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indices



This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.

Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Steve Grobet / Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr